NNIT Facilitates Seamless Transition to New Electronic Data Capture Platform for Top 20 Biopharma Pioneer

NNIT completes successful collaboration with a Top 20 Biopharma pioneer in transitioning to a new Electronic Data Capture (EDC) platform for their clinical trials.

Recognizing the compelling benefits of the new EDC platform, the customer embarked on their transformational journey with meticulous attention to mitigating risks associated with moving active clinical studies data.

A seamless migration process was underpinned by NNIT's commitment to maintaining GxP data integrity and ensuring minimal disruption to ongoing clinical trials. Working closely with both internal C-level stakeholders, external partners, and health authorities, NNIT devised a rigorous validation and independent verification approach tailored to each active study migration.

100% Automated Verification of Study Configurations and Data Points

Utilizing NNIT’s proprietary Valiance TRUcompare™ software, the team executed 100% automated verification of all study configurations and each data point, enabling early identification of migration issues, and minimizing potential disruptions to study teams. This meticulous approach, combined with NNIT's extensive clinical data management expertise, ensured the delivery of trusted clinical trial data at scale.

"NNIT's clinical data management experience and data migration verification capabilities empowered our customer to transition smoothly to a single new EDC platform with confidence," says Greg Cathcart, Senior Vice President of the U.S. Region at NNIT, and he continues: "Our automated independent verification process played a pivotal role in safeguarding against unintended bias during the study data transfer process."

The adoption of NNIT’s faster, repeatable, predictable, and traceable migration verification process across the enterprise portfolio of active studies enabled the customer to circumvent the risks associated with parallel activity in twin EDC systems.